(CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November 26, 2019? Should Management be Held Accountable for Investors Losses?

SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) against certain of its current and former officers and directors. 

Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of ChemoCentryx from November 26, 2019 and May 6, 2021 (the "Class Period").

The Complaint alleges that the Company failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's NDA for avacopan for the treatment of ANCA associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

If you are a current, long-term shareholder of ChemoCentryx, holding shares before November 26, 2019, you may have standing to hold ChemoCentryx harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. 

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number. 

Additionally, if you are a current, long-term shareholder of ChemoCentryx, holding shares before November 26, 2019, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

View original content:https://www.prnewswire.com/news-releases/ccxi-long-term-investor-alert-did-you-acquire-chemocentryx-before-november-26-2019-should-management-be-held-accountable-for-investors-losses-301326920.html

SOURCE Johnson Fistel, LLP